Atopic dermatitis (AD) is characterized by intensive itching and recurrent eczematous skin lesions. Genetic susceptibility, impaired skin barrier, dysregulated immune responses, and environmental exposures coordinately contribute to the pathophysiology of AD. The intensive itch in AD leads to poor sleep and loss of quality of life. In this session, the significance and treatment of sleep disorder present in AD are reviewed By Dr. Chang. AD as a multifactorial disease, how the precision medicine would affect the clinical decision and judgement about the disease severity, treatment, prognosis, comorbidities, along with its challenges and chances are reviewed by Dr. Wang. Dr. Lee summarize how the dysregulated innate and adaptive responses along with the increased neuropeptides (i.e. endorphin) lead to itch in AD. The central processing of itch and pain signal is measured and compared by near infrared spectroscope (NIRS). Dr. Lin discusses how the impaired skin barrier results in the disease flare up and how the barrier restoration prevents the disease worsening. Finally, Dr. Tsai updates the current treatment for AD and summaries the treatment perspective, including medications against Th2 cytokines and intracellular signals.
　　Multidisciplinary approaches are required to disentangle the AD pathogenesis, focusing on the genetic and environmental interactions in terms of precision medicine, including epidemiology, genomics, epigenomics, exposures, microbiomics, and functional animal studies.